Abstract
Despite significant development of melanoma therapies, death rates remain high. MicroRNAs, controlling posttranscriptionally gene expression, play role in development of resistance to BRAF inhibitors. The aim of the study was to assess the role of miR-410-3p in response to vemurafenib-BRAF inhibitor. FFPE tissue samples of 12 primary nodular melanomas were analyzed. With the use of Laser Capture Microdissection, parts of tumor, transient tissue, and adjacent healthy tissue were separated. In vitro experiments were conducted on human melanoma cell lines A375, G361, and SK-MEL1. IC50s of vemurafenib were determined using MTT method. Cells were transfected with miR-410-3p mimic, anti-miR-410-3p and their non-targeting controls. ER stress was induced by thapsigargin. Expression of isolated RNA was determined using qRT-PCR. We have found miR-410-3p is downregulated in melanoma tissues. Its expression is induced by vemurafenib in melanoma cells. Upregulation of miR-410-3p level increased melanoma cells resistance to vemurafenib, while its inhibition led to the decrease of resistance. Induction of ER stress increased the level of miR-410-3p. miR-410-3p upregulated the expression of AXL in vitro and correlated with markers of invasive phenotype in starBase. The study shows a novel mechanism of melanoma resistance. miR-410-3p is induced by vemurafenib in melanoma cells via ER stress. It drives switching to the invasive phenotype that leads to the response and resistance to BRAF inhibition.
Highlights
Melanoma is a skin cancer that derives from melanocytes
Results miR-410-3p is downregulated in untreated melanoma tumors miR-410-3p has a divergent role in molecular oncology and may act as either oncomiR or tumor suppressor miR
We found that the expression of miR-410-3p was significantly induced 48h and 96h after vemurafenib was administered in melanoma cell lines (Fig 2a)
Summary
Melanoma is a skin cancer that derives from melanocytes. It is the deadliest type of skin cancer with the incidence rate of 19.7 per 100,000 and the age-adjusted death rate 2.7 per 100,000. Despite of awareness of well-known risk factors such as sunburn, long sun exposure, and indoor tanning, incidence rates continue to increase [1]. In recent years a significant improvement of melanoma therapies based on targeted therapy and immune therapy is observed, but still, an estimated median survival for patients with.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.